CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 300 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Dexamethasone 0.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05567094
NCT05567094Phase 4Completed
CompareCT.gov

The Effect of Perioperative DEXamethasone on Postoperative Complications After PANcreaticoduodenectomy

Ruijin Hospital·interventional·Posted Oct 5, 2022·Updated Sep 18, 2023

In Brief

A Phase 4 clinical trial evaluating Dexamethasone and Saline placebo for Pancreaticoduodenectomy. Completed, enrolled 300 participants across 1 site.

Detailed Summary

The primary objective of this clinical trial is evaluate the effect of dexamethasone on postoperative complications after pancreaticoduodenectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreaticoduodenectomy
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedOct 5, 2022
Enrollment StartOct 8, 2022
Primary CompletionSep 14, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.7 years ago

Interventions

Dexamethasonedrug

Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia

Saline placebodrug

Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia